A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(9 sites)
Australia
St Vincent's Hospital, Sydney, New South Wales Integrated Clinical Oncology Network (ICON) Pty Ltd, Woolloongabba, Queensland The Alfred Hospital, Melbourne, Victoria Linear Clinical Research, Murdoch, Western Australia South Korea
Pusan National Univesity Hospital, Busan Cha University Bundang Medical Center, Gyeonggi-do Seoul National University Hospital, Seoul Taiwan
National Taiwan University Hospital, Taipei Taipei Tzu Chi Hospital, Taipei Last updated December 2025